New Leaf Venture Partners, L.L.C is an investment fund managing more than $116 billion ran by Craig Slutzkin. There are currently 14 companies in Mr. Slutzkin’s portfolio. The largest investments include Arvinas Inc and Rallybio Corporation, together worth $50.7 billion.
As of 3rd August 2023, New Leaf Venture Partners, L.L.C’s top holding is 1,289,521 shares of Arvinas Inc currently worth over $32 billion and making up 27.5% of the portfolio value.
Relative to the number of outstanding shares of Arvinas Inc, New Leaf Venture Partners, L.L.C owns more than approximately 0.1% of the company.
In addition, the fund holds 3,301,603 shares of Rallybio Corporation worth $18.7 billion.
The third-largest holding is Dice Therapeutics Inc worth $17.3 billion and the next is Deciphera Pharmaceuticals Inc worth $17 billion, with 1,209,571 shares owned.
Currently, New Leaf Venture Partners, L.L.C's portfolio is worth at least $116 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The New Leaf Venture Partners, L.L.C office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Craig Slutzkin serves as the Chief Financial Officer at New Leaf Venture Partners, L.L.C.
In the most recent 13F filing, New Leaf Venture Partners, L.L.C revealed that it had opened a new position in
Rocket Pharmaceuticals Inc and bought 118,242 shares worth $2.35 billion.
This means they effectively own approximately 0.1% of the company.
Rocket Pharmaceuticals Inc makes up
3.4%
of the fund's Health Care sector allocation and has grown its share price by 0.3% in the past year.
The investment fund also strengthened its position in Rallybio Corporation by buying
1,000,000 additional shares.
This makes their stake in Rallybio Corporation total 3,301,603 shares worth $18.7 billion.
On the other hand, there are companies that New Leaf Venture Partners, L.L.C is getting rid of from its portfolio.
New Leaf Venture Partners, L.L.C closed its position in Sierra Oncology Inc on 10th August 2023.
It sold the previously owned 219,251 shares for $12.1 million.
Craig Slutzkin also disclosed a decreased stake in Dice Therapeutics Inc by 0.3%.
This leaves the value of the investment at $17.3 billion and 371,693 shares.
The two most similar investment funds to New Leaf Venture Partners, L.L.C are Disciplined Equity Management and Geneva Partners. They manage $116 billion and $116 billion respectively.
New Leaf Venture Partners, L.L.C’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 58.8% of
the total portfolio value.
The fund focuses on investments in the United States as
71.4% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
21% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $691 million.
These positions were updated on August 10th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Arvinas Inc |
No change
1,289,521
|
$32,005,911,000 | 27.49% |
| Rallybio Corporation |
43.45%
3,301,603
|
$18,687,073,000 | 16.05% |
| Dice Therapeutics Inc |
33.23%
371,693
|
$17,268,857,000 | 14.83% |
| Deciphera Pharmaceuticals Inc |
No change
1,209,571
|
$17,030,760,000 | 14.63% |
| Edgewise Therapeutics Inc |
No change
1,553,661
|
$12,040,873,000 | 10.34% |
| Cogent Biosciences, Inc. |
No change
501,530
|
$5,938,115,000 | 5.10% |
| Crinetics Pharmaceuticals Inc |
No change
141,000
|
$2,540,820,000 | 2.18% |
| Rocket Pharmaceuticals Inc |
Opened
118,242
|
$2,349,469,000 | 2.02% |
| Passage Bio Inc |
No change
2,497,922
|
$2,348,047,000 | 2.02% |
| Harpoon Therapeutics, Inc. |
No change
3,156,699
|
$2,241,256,000 | 1.92% |
| Alector, Inc. |
No change
339,569
|
$2,040,810,000 | 1.75% |
| Aravive Inc |
No change
946,423
|
$1,192,493,000 | 1.02% |
| X4 Pharmaceuticals, Inc. |
No change
335,000
|
$649,900,000 | 0.56% |
| Iterum Therapeutics Plc |
Opened
97,084
|
$103,880,000 | 0.09% |
| Sierra Oncology Inc |
Closed
219,251
|
$12,057,000 | |
| Amryt Pharma plc |
Closed
449,737
|
$3,144,000 | |
| Chimerix Inc |
Closed
1,224,600
|
$2,547,000 | |
| Aptinyx Inc |
Closed
3,290,079
|
$1,836,000 | |
| Renovacor Corporation |
Closed
670,689
|
$1,360,000 | |
| PDS Biotechnology Corporation |
Closed
117,242
|
$428,000 | |
| Iterum Therapeutics Plc |
Closed
1,456,303
|
$292,000 | |
| AvroBio Inc |
Closed
315,550
|
$290,000 | |
| Addex Therapeutics Ltd |
Closed
50,000
|
$58,000 | |
| No transactions found | |||
| Showing first 500 out of 23 holdings | |||